依特卡肽治疗糖尿病肾病维持性血液透析继发甲状旁腺功能亢进的疗效观察  

Efficacy of etelcalcetide in the treating of secondary hyperparathyroidism to maintenance hemodialysis in diabetic nephropathy

作　　者：马世兴[1] 仇琳[1] 王勤超[1] MA Shi-xing;QIU Lin;WANG Qin-chao(Department of Diabetes Mellitus,Department of Nephrology,Division of Nephrology,Baoji Central Hospital,Baoji 721008,Shaanxi,China)

机构地区：[1]宝鸡市中心医院肾病内科糖尿病科,陕西宝鸡721008

出　　处：《川北医学院学报》2024年第8期1049-1051,1055,共4页Journal of North Sichuan Medical College

基　　金：陕西省社会发展科技攻关项目(2020A089)。

摘　　要：目的:探究依特卡肽治疗糖尿病肾病维持性血液透析(MHD)继发性甲状旁腺功能亢进(SHPT)的疗效。方法:根据治疗药物不同将92例糖尿病肾病MHD引起的SHPT患者分为研究组和对照组,每组各46例。研究组给予依特卡肽治疗;对照组给予西那卡塞治疗,两组均持续治疗3个月。比较治疗前后的两组患者的甲状旁腺指标、生化指标、成纤维细胞生长因子23(FGF23)水平、骨代谢指标差异;记录并比较两组患者不良反应发生情况。结果:治疗后,两组患者甲状旁腺指标、生化指标、FGF23水平、骨代谢指标均降低(P<0.05),且研究组低于对照组(P<0.05);研究组患者不良反应发生率低于对照组(P<0.05)。结论:依特卡肽治疗糖尿病肾病MHD继发SHPT患者可有效改善患者甲状旁腺功能。Objective:To explore the effect of etelcalcetide on secondary hyperparathyroidism(SHPT)in maintenance hemodialysis(MHD)of diabetic nephropathy.Methods:92 patients with SHPT caused by diabetic nephropathy MHD were divided into study group(46 cases)and control group(46 cases)by using different therapeutic drugs.The study group was treated with etelcalcetide,while the control group was given cinacalcet,and both groups were treated continuously for 3 months.The differences in parathyroid indicators,biochemical indices,fibroblast growth factor 23(FGF23)levels,bone metabolism indicators before and after treatment were compared between the two groups.The incidence of adverse reactions of the two groups was recorded.Results:After treatment,the thyroid indicators,serum indicators,FGF23 levels and bone metabolism indicators of patients were decreased(P<0.05),and the above indicators in study group were lower(P<0.05).The incidence rates of adverse reactions in study group were lower than those in control group(P<0.05).Conclusion:Etelcalcetide can effectively improve the parathyroid function in patients with SHPT secondary to MHD of diabetic nephropathy.

关 键 词：糖尿病肾病 维持性血液透析 继发性甲状旁腺功能亢进 甲状腺指标 

分 类 号：R587.2[医药卫生—内分泌] R692.5[医药卫生—内科学]